Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 0.64 |
| ▸ | CHRNB4 | P30926 | 20/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 20/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 20/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 18/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25372135 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL25391666 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL5773702 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3792324 | 0.98 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL29134669 | 0.93 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL25370321 | 0.91 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6318814 | 0.89 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL23189549 | 0.85 | CHRNA4 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL21143524 | 0.85 | CHRNA4 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL25428256 | 0.85 | CHRNA4 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025242908-A2 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4615581-A2 | FUSED MULTICYCLIC COMPOUNDS AND THEIR USE AS PARP1 INHIBITORS | Laekna Pharmaceutical Ningbo Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| CN-116217593-B | Octahydropyrrolo [3,4-c ] pyrrole methyl ketone derivative and application thereof | 江苏恩华药业股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2024238793-A1 | FUSED TRIAZINONES FOR USE IN THE TREATMENT OF CANCER | RGENTA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4456895-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | Accro Bioscience (HK) Limited (HK) | 2024-11-06 | — | — | EP | disclosed |
| CN-118871445-A | Fused triazinone derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2006137791-A1 | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1360187-A1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | CHRNB2 3596/4885CHRNB4 4045/4885CHRNA3 3099/4885 |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | CHRNB2 634/4885CHRNB4 523/4885CHRNA3 262/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | CHRNB2 2015/4885CHRNB4 3634/4885CHRNA3 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.